Daratumumab is “major advancement” in the treatment of high-risk smoldering multiple myeloma
Researchers report that, among patients with high-risk smoldering multiple myeloma, treatment with daratumumab appears to be associated with a significantly lower risk of progression to active multiple myeloma… read more.
